Batch-to-Batch Variability Is a Design Failure, Not the Norm – Part 2
Biotech startups face a labyrinth of decisions when it comes to manufacturing strategy.
Batch-to-Batch Variability Is a Design Failure, Not the Norm – Part 1
What if batch-to-batch variability was no longer just “part of the job” in tissue engineering and in vitro biology?
Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection – Part 2
Cell line development in biotech is a race against time and complexity, with innovators constantly seeking solutions that provide robust and scalable data for manufacturability and regulatory demands.
Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection – Part 1
Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability.
When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2
Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.
When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 1
Imagine a delivery system that can slip straight into a cell’s membrane, bypassing the barriers that stop most genetic medicines in their tracks. While AAVs and lipid nanoparticles have charted the way for gene therapies, a new contender is emerging: proteolipid vehicles powered by viral fusion proteins.
Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines – Part 2
Manufacturing under GMP with no established playbook isn’t for the faint-hearted—especially when your therapeutic platform is first-in-class and the regulatory template hasn’t been written yet.
Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines – Part 1
What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?
From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic – Part 2
Translating science into real-world impact isn’t just about groundbreaking ideas—it’s a marathon of mindset, collaboration, and clarity.
From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic – Part 1
What if healing large tissue gaps was less about replacing what’s lost, and more about empowering the body to mend itself?